Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 6/20 | 0.39 |
| ▸ | MMP9 | P14780 | 5/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834367 | 0.84 | ALDH1A1 (0.55) | CTSSALDH1A1MMP9CTSLCTSK | |
| SCHEMBL3365403 | 0.84 | ALDH1A1 (0.55) | CTSSALDH1A1MMP9CTSLCTSK | |
| SCHEMBL21387168 | 0.82 | ALDH1A1 (0.50) | CTSSALDH1A1MMP3MMP9BIRC2 | |
| SCHEMBL3923432 | 0.82 | CTSB (0.49) | CTSSALDH1A1CTSKBACE1 | |
| SCHEMBL10378726 | 0.81 | NPY4R (0.46) | ALDH1A1 | |
| SCHEMBL10378723 | 0.81 | NPY4R (0.46) | ALDH1A1 | |
| SCHEMBL3426049 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MMP3MMP9SIRT6SIRT1 | |
| SCHEMBL7114227 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MMP3MMP9SIRT6SIRT1 | |
| SCHEMBL3426060 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MMP3MMP9SIRT6SIRT1 | |
| SCHEMBL3381459 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MMP3MMP9SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-08 | — | — | US | disclosed |
| EP-3046870-B1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | UNIV QUEENSLAND (AU) | 2021-08-11 | — | — | EP | disclosed |
| EP-2861217-B1 | NANOEMULSIONS | UNIV QUEENSLAND (AU) | 2017-09-06 | — | — | EP | disclosed |
| US-9554995-B2 | Nanoemulsions | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-01-31 | — | — | US | disclosed |
| US-20160193581-A1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-20150132395-A1 | NANOEMULSIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-05-14 | — | — | US | disclosed |
| EP-2861217-A1 | NANOEMULSIONS | The University Of Queensland (AU) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013185178-A1 | NANOEMULSIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193581-A1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | SGMS2, SGMS1, PHOSPHO1 | CTSS 160/4885ALDH1A1 4682/4885MMP3 3576/4885 |
| US-20150132395-A1 | NANOEMULSIONS | LNPEP, IAPP, CETP | CTSS 1699/4885ALDH1A1 4632/4885MMP3 1639/4885 |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | SGMS2, PHOSPHO1, SOST | CTSS 441/4885ALDH1A1 4784/4885MMP3 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.